In this context, the development of new CRF1 antagonists such as NGD 98-2 and NGD 9002 that have better oral bioavailability opens new venues to understand the potential role and mechanisms of CRF1 receptors in stress-sensitive functional bowel disorders such as IBS. Here, CRHR1 is linked to irritable bowel syndrome.